Target intelligence / Profile preview

Nuclear factor NF-kappa-B subunit 1 (NFKB1)

Target
NFKB1
Molecular classification
Transcription factor, DNA-binding protein
01

Overview

Nuclear factor NF-kappa-B subunit 1 (NFKB1) is a key component of the NF-κB transcription factor complex, expressed as a 105 kDa precursor protein (p105) that is proteolytically processed to generate the 50 kDa p50 subunit. NFKB1 is involved in regulating transcription of genes critical for immune and inflammatory responses, cell proliferation, survival, and apoptotic resistance. In its inactive state, NF-κB complexes are sequestered in the cytoplasm by inhibitor proteins (IκBs); activation involves IκB degradation, freeing NF-κB dimers such as p50/RelA to translocate into the nucleus and control gene transcription. NFKB1 can act as a transcriptional activator or repressor depending on its dimerization partners and cellular context, playing major roles in cancer, inflammation, immunity, and various diseases. It is a validated therapeutic target, with several approved and investigational drugs acting by directly or indirectly modulating the NF-κB pathway.

Other names
p105p50NF-κB1NF-kappa-B subunit 1Nuclear factor kappa B subunit 1
02

Mechanism of action

Inhibition of NF-κB activation Blockade of IκB degradation/proteasome function Inhibition of upstream kinase (IKK complex) Direct DNA binding blockade (investigational)

03

Biological functions

Regulation of transcriptionImmune responseInflammationCell proliferationCell survival/anti-apoptosisSignal transduction
04

Disease associations

CancerInflammationAutoimmune diseaseInfectionNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Immunosuppression leading to increased infection riskPotential impairment of normal cell survival and tissue homeostasisOff-target effects due to the pleiotropic role of NF-κB in many cell types
06

Interacting drugs

Bortezomib (indirect inhibitor via proteasomal blockade)

3 more in the full profile.

07

Biomarkers

NF-κB nuclear localization (marker of pathway activation)Expression of NF-κB target genes (e.g., cytokines such as IL-6, TNFα)p50 or p105 expression/protein abundance

Beyond the preview

Go deeper on Nuclear factor NF-kappa-B subunit 1 (NFKB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor NF-kappa-B subunit 1 (NFKB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call